Health Care
Osteopore Limited (OSX)
Osteopore Limited (ASX: OSX) is a medtech company developing proprietary 3D printed scaffolds for tissue regeneration, focusing on bone repair. Operating in Australia with products under development for global markets, its key product is a bioresorbable scaffold for orthopedic and craniofacial applications. Based in Perth, Western Australia, it leverages local research partnerships.
Market Cap
A$5M
Shares on Issue
N/A
Price Chart
AI Analysis
As of listing in September 2019, OSX remains in the development stage with no commercial revenue, characteristic of early-stage medtech companies. Its market cap of A$5M reflects its speculative, high-risk profile. Recent performance is tied to research milestones and capital raisings.
Growth prospects hinge on successful clinical trials, regulatory approvals (e.g., FDA, CE Mark), and strategic partnerships for commercialization. Upcoming catalysts may include trial data releases or licensing agreements, guiding its strategic direction towards global market entry.
Bull Case
- • Successful clinical trials leading to rapid regulatory approval and market adoption of its 3D printed scaffolds.
- • Strategic partnership or licensing deal with a major global healthcare company, providing capital and distribution networks.
- • First-mover advantage in theﾚglobal 3D printed bone graft market, estimated to grow significantly by 2025.
Bear Case
- • Failure in clinical trials, halting product development and diminishing investor confidence.
- • Intense competition from established medical device manufacturers entering the 3D printing space.
- • Capital raising challenges due to market sentiment, hindering progress towards commercialization.
Market Sentiment
Based on 7 social posts
Recent mentions
Discussion of regulatory definitions and company structure
OSX announces change in substantial holding
OSX announces change in substantial holding
Recent Announcements
Change in substantial holding
Application for quotation of securities - OSX
Ceasing to be a substantial holder
Activities Report December 2025 and Appendix 4C
🚨 Price SensitiveThe ASX announcement for ticker OSX details the commitments test entity's quarterly report on activities as of December 2term, with a focus in Appendix 4C. Investors should review these detailed financial and operational insights to assess current performance trends and
OSX bolsters digital design, eyes HK Centre of Excellence
FAQs
What does OSX do?
Osteopore develops and commercializes 3D printed, bioresorbable scaffolds for tissue repair, initially focusing on bone regeneration.
Is OSX a good investment?
OSX offers high-risk, high-reward potential typical of early-stage medtech. Success depends on clinical and regulatory milestones; investors should assess tolerance for speculative investments.
What drives OSX's share price?
Share price is driven by clinical trial outcomes, partnership announcements, capital raising success, and broader ASX biotech sector sentiment.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.